Skip to content

Daclatasvir Impurity 3

Daclatasvir Impurity 3

Product Description
CAT No.
ALN-D036025
CAS No.
1009119-82-7
Mol. F.
C36H44N2O10
Mol. Wt.
664.8
Stock
Please Inquire
RFQ
Chemical Name : O’2,O2-([1,1′-Biphenyl]-4,4′-diylbis(2-oxoethane-2,1-diyl)) 1,1′-di-tert-butyl (2S,2’S)-bis(pyrrolidine-1,2-dicarboxylate)
Smiles : O=C([C@H]1N(C(OC(C)(C)C)=O)CCC1)OCC(C2=CC=C(C3=CC=C(C(COC([C@H]4N(C(OC(C)(C)C)=O)CCC4)=O)=O)C=C3)C=C2)=O
Inchi : InChI=1S/C10H17NO4/c1-10(2,3)15-9(14)11-6-4-5-7(11)8(12)13/h7H,4-6H2,1-3H3,(H,12,13)/t7-/m0/s1

A validated stability-indicating reverse-phase high-performance liquid chromatography method for daclatasvir, identification and characterization of degradation products using LC-ESI-QTOF-MS

By Warghade, Snehal V.; Bothara, Kailash G.nFrom Asian Journal of Pharmaceutical and Clinical Research (2019), 12(5), 302-308

Development and validation of HPLC fluorescence and UPLC/DAD stability-indicating methods for determination of hepatitis C antiviral agent daclatasvir

By Kamal, Andra H.; Ismail, Nahla S.; Mabroijk, Mokhtar M.; Bebawy, Lories I.; Mekky, Mai A. – From Journal of AOAC International (2019), 102(4), 1125-1131

A stability-indicating UPLC method for the determination of potential impurities and its mass by a new QDa mass detector in daclatasvir drug used to treat hepatitis C infection

By Jagadabi, Varaprasad; Kumar, P. V. Nagendra; Mahesh, Kasthuri; Pamidi, Srinivasu; Ramaprasad, L. A.; Nagaraju, D. – From Journal of Chromatographic Science (2019), 57(1), 44-53

Request For Quotation